Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination Wegovy ...

The company CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade probe ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...